CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.
about
CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1A double-edged kinase Lyn: a positive and negative regulator for antigen receptor-mediated signalsInhibition of the B cell by CD22: a requirement for LynSustained activation of Lyn tyrosine kinase in vivo leads to autoimmunityInterference with immunoglobulin (Ig)alpha immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an Igbeta cytoplasmic tailSiglecs in the immune systemSiglecs as sensors of self in innate and adaptive immune responsesSiglecs and immune regulationCD22 and Siglec-G in B cell function and toleranceRethinking mechanisms of autoimmune pathogenesisIntravital imaging of Ca(2+) signals in lymphocytes of Ca(2+) biosensor transgenic mice: indication of autoimmune diseases before the pathological onset.CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium fluxCD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1CD22: an inhibitory enigmaDefinition of the sites of interaction between the protein tyrosine phosphatase SHP-1 and CD22B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esteraseAnalysis of tyrosine phosphorylation-dependent interactions between stimulatory effector proteins and the B cell co-receptor CD22Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signalingCloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells.Amplified B lymphocyte CD40 signaling drives regulatory B10 cell expansion in mice.Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm.Siglecg limits the size of B1a B cell lineage by down-regulating NFkappaB activationAugmented B lymphocyte response to antigen in the absence of antigen-induced B lymphocyte signaling in an IgG-transgenic mouse lineDecoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivoApotosis of mature B cells.A balance between B cell receptor and inhibitory receptor signaling controls plasma cell differentiation by maintaining optimal Ets1 levelsB-cell homeostasis requires complementary CD22 and BLyS/BR3 survival signals.Lessons from BXSB and related mouse models.CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemiaNew functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs.Targeting B cells with biologics in systemic lupus erythematosus.Ig beta tyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internalization.CD19, CD21, and CD22: multifaceted response regulators of B lymphocyte signal transduction.ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signalingCD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouseCD22 regulates adaptive and innate immune responses of B cells.B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosisUp regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis.Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
P2860
Q24554515-39B50948-9EA9-4445-B30C-5B2E5FAC0175Q24647322-7D756ED6-50DB-4E1B-B08A-75295F845CEEQ24647368-13FE8B3A-8838-46F1-98FA-628F4B3B2D7BQ24670363-25652371-7076-486D-BB0B-D0163046F753Q24675475-21A50DCF-5004-45CA-9D4F-D7FE32FCC745Q24682458-C117CF89-A18A-40BE-8E22-1C7E5E9CEFBFQ26829757-0500FF64-4FB2-452A-AA0D-74CE01E59715Q26992091-1A3CA166-42DA-48A3-8800-3AFD056D4A20Q27016111-2F7871E5-7F1C-4DEF-BAFB-90B6F4925C8EQ27024290-B44D2B54-AB16-4889-A08E-4E3CC703F5AAQ27302939-4879A50F-C102-4B2E-AFDE-9512724885B2Q28140639-C8103EC7-B987-4505-9C46-7BD0149D1AF0Q28215970-7C38EDDA-3B04-4D02-8075-866D64581F64Q28260435-DD4D2CB3-31A9-4829-8183-9D9B8C4FC0A8Q28294099-B54156FC-0CA5-48B2-8043-D22968F6A0ACQ28304887-1CA0D362-E9A2-440E-84BA-9D42C6C60B6BQ28505152-42A5B8C0-ABCD-4DC0-9A9C-ABF015D91028Q28613809-50948D72-1E34-4998-89D8-338BA28A0BDEQ30669536-E0778BFA-55A7-4C4F-95FF-705854D9EC27Q31027910-DFC5F999-AA6E-49C9-AD65-86B4A36E6132Q33217186-F03C56B5-3DCB-40F7-92C7-3C1962D5C9A7Q33301349-46E417AB-0853-4ADA-BF46-352AB2598EC4Q33526305-FE585D95-AAB3-4273-A951-4A1938E9EB3DQ33615157-16AE07AF-84F7-4D3F-8D01-79B01394D65AQ33811739-4ED6033E-AFA4-47EF-8EDA-A87924C86A16Q33849420-79468643-C7C7-4EF5-9909-53220A7621F3Q34013562-EA04196E-4B30-440F-843F-AFFAFD6273C4Q34052004-9943769E-97B8-44C4-82B4-0F1711E01DEDQ34165735-67FE5D95-D520-49D3-A0F8-29ED8CEFBD9CQ34184901-F32ED9A7-BE50-4DA9-958F-A8975826CD8BQ34232326-FFCB165F-A239-4086-884B-559EC4D2126AQ34544332-6E7B5333-A38E-4480-9226-8B440BE30B2CQ34577064-4CAA8CB6-CD25-4449-83D3-265F762B3478Q34718297-617E7C95-3918-4040-8FFC-E782A6557085Q34792036-7E8DB290-E4DA-4696-8BB6-CFCF3E30B15AQ35089756-008EC077-0718-4C91-88E2-A305AF0DB061Q35102984-12CD61E7-A261-4EE0-BC08-552DE5CAC51CQ35222002-68010C7D-AF2A-4977-BA1F-88C31B271AA5Q35554610-F0919F1E-FEF2-4447-8B18-49A399B245C7Q35605535-44B8D790-C17F-41FE-B75B-C931A201432E
P2860
CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
CD22 is both a positive and ne ...... naling in CD22-deficient mice.
@en
CD22 is both a positive and ne ...... naling in CD22-deficient mice.
@nl
type
label
CD22 is both a positive and ne ...... naling in CD22-deficient mice.
@en
CD22 is both a positive and ne ...... naling in CD22-deficient mice.
@nl
prefLabel
CD22 is both a positive and ne ...... naling in CD22-deficient mice.
@en
CD22 is both a positive and ne ...... naling in CD22-deficient mice.
@nl
P2093
P1433
P1476
CD22 is both a positive and ne ...... naling in CD22-deficient mice.
@en
P2093
P304
P356
10.1016/S1074-7613(00)80270-8
P407
P577
1996-12-01T00:00:00Z